Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – The Cannabis and Psychedelics sectors received a mix of signals over the last fortnight: from regulatory delays and scientific breakthroughs to market consolidation and a wave of Q1 2026 earnings – all adding up to an industry that is finding its commercial footing even as political clarity remains elusive. Below we’ve outlined the key takeaways, what’s worth a second look, and what operators should be tracking into Q2.

1. The Federal Layer Shifts Under Everyone’s Feet

The DEA rescheduling window analysis reframed a debate the industry has been conducting on the wrong terms. The real contest is not over scheduling, but rather, which Cannabis products earn the classification of “medical” under a reformed federal framework. That definitional question will determine market access, product eligibility, banking relationships, and institutional investment thresholds for years. Operators who have spent the last eighteen months preparing clinical documentation and pharmaceutical-grade compliance infrastructure understand this intuitively. The ones still waiting for a single legislative event to unlock everything are misreading the mechanism.

When the FDA granted Breakthrough Therapy Designation to Vertanical’s VER-01, a Cannabis-derived, non-opioid investigational drug for pain, the decision landed with more weight than a routine agency notice. Breakthrough Therapy Designation is not ceremonial. It accelerates development and positions a compound for serious regulatory attention. For an industry that has spent decades fighting for scientific legitimacy inside federal corridors, Vertanical’s milestone is a proof point that the FDA’s doors are opening, if slowly, to plant-derived therapeutics.

2. Q1 2026 Earnings Season Wrap-Up

The Q1 2026 earnings arrived in volume, revealing an industry where survival has become a form of competitive advantage. Cresco Labs, Glass House Brands, and Planet 13 each reported against a backdrop of margin compression and persistent tax burden, while MariMed  and Grown Rogue signaled operational discipline in leaner operating footprints.

Cronos Group, Organigram, Rubicon Organics, and Decibel rounded out a picture of Canadian operators managing costs tightly while watching U.S. federal developments with strategic patience. Village Farms, Vireo Growth, iAnthus, and Jushi each brought their own set of operational realities to Q1, and none of them suggested the sector is in retreat.

3. Consumer Behavior Reshapes the Medical Argument

A new study on older Americans turning to Cannabis as a pharmaceutical alternative drew significant attention from industry observers, and for good reason. Adults over 65 are approaching Cannabis not as a lifestyle choice but as a deliberate healthcare decision, one driven by dissatisfaction with pharmaceutical side-effect profiles, cost burdens, and inadequate management of chronic pain, sleep disruption, and anxiety. This population did not grow up with Cannabis culture. They found their way to Cannabis through the front door of medical necessity, and it looks like they’re here to stay.

Leafwell, bringing medical Cannabis into the employee benefits structure, is the institutional expression of the same demand. When benefits administrators begin treating Cannabis access as a line item alongside telehealth and mental health coverage, the distribution channel for medical operators changes fundamentally. Employer-sponsored access is an untapped option in our industry. Leafwell is shaping that path.

4. The Regulatory Gaps That Keep Costing Pretty Penny

Virginia’s Cannabis licensing expansion was vetoed by Governor Spanberger, pushing the state’s competitive licensing timeline back for the second time. The market is not dead, but delays extract real costs from operators who have been planning and capitalizing against a timeline that keeps shifting. Virginia remains a significant future market. It is the execution runway that remains uncertain.

The TSA’s decision to list medical Cannabis as permitted on its website while leaving the actual rules page blank is the most accurate metaphor for U.S. Cannabis policy in 2026. The signal exists. The framework does not. Patients are left to interpret silence, and this silence in a regulated industry carries risks.

Hemp regulation continues to generate friction. Cannabis and alcohol industry groups oppose the proposed hemp legislation, showcasing the structural tension between the two markets, which share shelf space and consumer attention, yet operate under entirely different regulatory regimes. This conflict will not be resolved without legislative clarity, which is still months, if not years, away.

5. Market Architecture & Capital Flow

Apollo’s $1.5 billion acquisition of Emerald [the parent company of MJBizCon] sent a clear message: institutional capital views Сannabis media and events infrastructure as a durable asset. The question for the industry is what Apollo’s ownership means for MJBizCon’s editorial independence and operator relationships. Observers, however, interpret this development as strategic consolidation in specialized media rather than a pure Cannabis bet, raising thoughtful considerations about the future direction of premier gatherings while confirming confidence in their long-term role.

Globally, IMARC Group projects European medical Сannabis reaching $13 billion by 2034, and a Research and Markets report sets a $28 billion target on Сannabis technology.

Bioxyne’s almost simultaneous market entries in Latin America and Europe show how international operators are moving on multiple geographies in parallel – a playbook unavailable to most U.S. operators under current federal restrictions.

6. Building for What Comes Next

Planet 13’s Florida approval for its BHO extraction lab, the Cannabis 3.0’s framework for platform-based industry development, Rob Van Dam’s hemp-derived e-commerce launch, and the ongoing UK medical Cannabis market analysis all reflect operators doing the same thing: extending their reach into the distribution and access infrastructure that will determine commercial position in the next regulatory cycle, regardless of what that cycle delivers.

7. Psychedelics Science Advances

Colorado’s passage of a landmark ibogaine research bill extended the state’s natural medicine framework into the territory few expected to move this fast. Ibogaine, long studied for addiction interruption, particularly opioid dependency, now has formal state-level research infrastructure backing its clinical future in Colorado.

In parallel, Definium dosed its first patient in a second Phase 3 LSD-based clinical trial, advancing the most robust psychedelic clinical pipeline currently operating in the U.S. Two active Phase 3 programs running concurrently represents a commercial confidence level that the psychedelics space has not seen before. Taken together with Colorado’s ibogaine infrastructure move, it is clear that plant and psychedelic medicine is no longer operating on hope and anecdote. It is operating on data.

HCN Insight

The market formation in Cannabis and Psychedelics has decoupled from the federal legislative calendar. Clinical pipelines are enrolling patients. Institutional capital is deploying at scale. Consumer adoption is expanding into demographics that carry long-term healthcare spending power. State governments are building research and licensing infrastructure on their own authority. None of this waited for a federal green light, and none of it will pause for one.

That decoupling carries a specific implication for capital allocation. The value in this sector is no longer concentrated in the companies best positioned to benefit from a single federal event. It is concentrated in the businesses that have built durable commercial infrastructure (clinical evidence, distribution access, extraction capacity, benefits integration) that compounds in value regardless of the regulatory sequence. The difference between those two investment theses is material, and the earnings, deals, and science from this fortnight draw the line between them with unusual clarity.

The industry’s most productive orientation right now is forward execution, not regulatory anticipation. The market has been telling that to anyone paying close enough attention for several years. The past two weeks made it harder to ignore.